glp 1 high heart rate and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference | American Journal of Physiology-Heart and Circulatory Physiology GLP-1 effect on resting heart

Patients were randomly assigned to orforglipron (12 mg or 36 mg) or semaglutide (7 mg or 14 mg) with a treatment period of 52 weeks, from 22 September 2022 to 22 August 2025, and drugs were administered orally once per day

Magic pills promising to help overweight people slim down are nothing new

Consequently, dual GLP-1/glucagon agonists survodutide, and triple GLP-1/GIP/glucagon agonists retatrutide are not spared gastrointestinal adverse events, as glucagon related pro-emetic signaling may offset any potential tolerability benefits from GIP agonism ( The contribution of amylin-based therapies to gastrointestinal adverse events remains less clear

Anti-emetic medications are generally not recommended as first-line treatment, as most nausea resolves with dietary adjustments and time